Document is current
Any future updates will be listed below
-
Authors
Ohno, Shinji
Mukai, Hirofumi https://orcid.org/0000-0002-9292-5128
Narui, Kazutaka
Hozumi, Yasuo
Miyoshi, Yasuo
Yoshino, Hiroshi
Doihara, Hiroyoshi
Suto, Akihiko
Tamura, Motoshi
Morimoto, Takashi
Zaha, Hisamitsu
Chishima, Takashi
Nishimura, Reiki
Ishikawa, Takashi
Uemura, Yukari
Ohashi, Yasuo
-
Funding
Funding for this research was provided by:
the Comprehensive Support Project for Oncology Research of the Public Health Research Foundation
- License Information
-
More Information
Article History
Received: 27 April 2019
Accepted: 9 May 2019
First Online: 21 May 2019
Compliance with ethical standards
:
: SO has received remuneration from Chugai, Eisai Pfizer, AstraZeneca, Kyowa Hakko Kirin, and Taiho; funding from Taiho, Eisai, Chugai, and Daiichi Sankyo. HM has received remuneration from Astra Zeneca, Pfizer, Daiichi Sankyo, Taiho, and Novartis; funding from Japanese government, Eisai, Daiichi Sankyo, and Nippon Kayaku, outside the submitted work. YM has received remuneration from Astra Zeneca, Chugai, Eisai, Taiho, Eli Lilly, Kyowa Hakko Kirin, and Novartis; funding from Eisai, Daiichi Sankyo, Kyowa Hakko Kirin, Chugai, Taiho, Eli Lilly, and MSD. HD has received funding from Eisai and Kyowa Hakko Kirin. YO has received consultant fee from Chugai, Daiichi Sankyo, and Sanofi. The other authors declare no competing interests.
: All procedures performed in study involving participants were in accordance with the ethical standards of the institutional or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
